FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Mad Mail: Does the iPhone Still Have a Chance in China?
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
- Why You Should Speculate on Stocks
- Next Week’s Top IPO
- Cramer: 5 Earnings Reports to Watch Next Week
- More Americans Lighting Up? Buy This Stock
- What Happened to Cypress Semi?
- Lightning Round: Raytheon, Salesforce.com, Pepsi and More
- Lightning Round OT: Apache, Brocade, Allergan and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Allergan seemed to have a day much like Foster Wheeler. Despite reporting strong quarterly numbers, analysts decided to harp on one weak-looking part of the business. The negativity took the stock down 3% Wednesday.
Here’s the story: Allergan [AGN
Loading...
()
] beat consensus estimates in both sales and earnings per share, and “blew out the numbers in R&D,” Chairman and CEO David Pyott said, registering 32% growth year-over-year. But it was concern over a dip in Botox’s U.S. performance that had Wall Street concerned.
Pyott begged investors to look at the big picture. Measured in constant currency, which excludes the benefits of a weak dollar, international Botox sales still grew at twice the rate as those in the U.S. So the overall business isn’t hurting.
Not to mention, Botox Cosmetic is only one small part of a big portfolio of Botox franchises, Pyott pointed out. And Botox accounts for a mere 10% of Allergan’s total sales.
The CEO called Wall Street’s reaction a short-term, saying that as long as “we just continue to deliver and perform, these things just iron themselves out.”
Cramer’s take? “At $52, this stock has gotten too cheap,” he said. “The analysts are too negative. This is your chance to buy Allergan.”
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes